Retiring CorMedix CEO Khoso Baluch

A month af­ter a man­u­fac­tur­ing hic­cup led to a CRL, CorMedix CEO will re­tire

Af­ter more than 5 years at the helm of New Jer­sey-based bio­phar­ma CorMedix, Khoso Baluch is re­tir­ing, and the move has trig­gered a rip­ple of change with­in its ex­ec­u­tive lead­er­ship team, lead­ing CFO Matt David to take over as in­ter­im CEO, while main­tain­ing his cur­rent role.

The de­par­ture comes about a month af­ter de­lays at a con­tract man­u­fac­tur­er led to the re­sub­mis­sion of a new drug ap­pli­ca­tion for De­fen­Cath, an an­tibac­te­r­i­al and an­ti­fun­gal treat­ment to pre­vent blood­stream in­fec­tions in pa­tients un­der­go­ing chron­ic he­modial­y­sis. The drug was grant­ed fast-track des­ig­na­tion by the FDA, but de­lays at the CMO’s site led to a com­plete re­sponse let­ter.

Stocks plum­met­ed 24% af­ter news of the de­lays broke. Be­fore the open­ing bell Tues­day, CorMedix’s stock was val­ued at $4.82. The FDA has ap­par­ent­ly told the com­pa­ny that the de­lays were un­re­lat­ed to the man­u­fac­tur­ing of De­fen­Cath.

David joined CorMedix in May 2020 as the CFO and EVP, com­ing over from Ovid Ther­a­peu­tics, where he spent about two years as the head of strat­e­gy. The ma­jor­i­ty of his ca­reer has been in health­care bank­ing, and he re­ceived his MD from New York Uni­ver­si­ty School of Med­i­cine in 2003.

As the com­pa­ny’s board of di­rec­tors — which Baluch al­so re­tired from — moves to re­place the for­mer CEO, Baluch will serve as an ad­vi­sor to en­sure a smooth tran­si­tion.

“I am hon­ored to take on the role of in­ter­im CEO dur­ing this im­por­tant time for the Com­pa­ny,” David said in the press re­lease. “With a strong ex­ec­u­tive team span­ning reg­u­la­to­ry, med­ical af­fairs, clin­i­cal op­er­a­tions and com­mer­cial, and a high­ly sup­port­ive board which in­cludes proven health­care in­dus­try lead­ers, I be­lieve we are well po­si­tioned to con­tin­ue our ef­forts to bring De­fen­Cath to the he­modial­y­sis pa­tient com­mu­ni­ty.”

John Arm­strong, the EVP for tech­ni­cal op­er­a­tions, al­so re­tired Mon­day. Phoebe Mounts, EVP and head of reg­u­la­to­ry com­pli­ance and le­gal, will have di­rect au­thor­i­ty over the com­pa­ny’s tech­ni­cal op­er­a­tions group, in­clud­ing a group of con­sul­tants that are work­ing on ad­dress­ing the sit­u­a­tion with the CMO.

My­ron Ka­plan, the chair­man of the board, said in a state­ment:

On be­half of the en­tire Board, I thank Khoso and Jack for their ded­i­cat­ed ser­vice and con­tri­bu­tions to CorMedix. Khoso has been in­stru­men­tal in re­fo­cus­ing the Com­pa­ny and guid­ing it strate­gi­cal­ly while build­ing a high­ly ex­pe­ri­enced ex­ec­u­tive team. Matt’s en­er­gy and lead­er­ship, with the sup­port of CorMedix’s Board of Di­rec­tors and ex­pe­ri­enced man­age­ment team, en­able him to con­tin­ue the im­por­tant work un­der­way to progress De­fen­Cath, while the CEO search is on­go­ing.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls



Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

SQZ Biotech slash­es head­count by 60% as founder/CEO hits ex­it — while Syn­log­ic lays off 25%

It’s a tough time for early-stage companies developing highly promising, but largely unproven, new technologies.

Just ask SQZ Biotechnologies and Synlogic. The former is bidding farewell to its founder and CEO and slashing the headcount by 60% as it pivots from its original cell therapy platform to a next-gen approach; the latter — a synthetic biology play founded by MIT’s Jim Collins and Tim Lu — is similarly “optimizing” the company to focus on lead programs. The resulting realignment means 25% of the staffers will be laid off.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Lynn Baxter, Viiv Healthcare's head of North America

Vi­iV dri­ves new cor­po­rate coali­tion in­clud­ing Uber, Tin­der and Wal­mart, aimed at end­ing HIV

ViiV Healthcare is pulling together an eclectic coalition of consumer businesses in a new White House-endorsed effort to end HIV by the end of the decade.

The new US Business Action to End HIV includes pharma and health companies — Gilead Sciences, CVS Health and Walgreens — but extends to a wide range of consumer companies that includes Tinder, Uber and Walmart.

ViiV is the catalyst for the group, plunking down more than half a million dollars in seed money and taking on ringmaster duties for launch today on World AIDS Day, but co-creator Health Action Alliance will organize joint activities going forward. ViiV and the alliance want and expect more companies to not only join the effort, but also pitch in funding.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Matt Gline, Roivant Sciences CEO (Photo by John Sciulli/Getty Images for GLG)

Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

Pfizer and Roivant are teaming up to launch a new ‘Vant’ aimed at bringing a mid-stage anti-inflammatory drug to market, the pair announced Thursday.

There’s no name for the startup yet, nor are there any employees. Thus far, the new company and Roivant can be considered “one and the same,” Roivant CEO Matt Gline tells Endpoints News. But Pfizer is so enthusiastic about the target that it elected to keep 25% of equity in the drug rather than take upfront cash from Roivant, Gline said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Roche HQ in Basel, Switzerland. (Image credit: Kyle LaHucik/Endpoints News)

As com­peti­tors near FDA goal­post, Roche spells out its re­peat Alzheimer's set­back

Before Roche can turn all eyes on a new version of its more-than-once-failed Alzheimer’s drug gantenerumab, the Big Pharma had to flesh out data on the November topline failure at an annual conference buzzier than in years past thanks to hotly watched rivals in the field: Eisai and Biogen’s lecanemab, and Eli Lilly’s donanemab.

There was less than a 10% difference between Roche’s drug and placebo at slowing cognitive decline across two Phase III trials, which combined enrolled nearly 2,000 Alzheimer’s patients. In its presentation at the conference Wednesday, Roche said it saw less sweeping away of toxic proteins than it had anticipated. For years, researchers and investors have put their resources behind the idea that more amyloid removal would equate to reduced cognitive decline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.